Found: 22
Select item for more details and to access through your institution.
Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
- Published in:
- 2011
- By:
- Publication type:
- commentary
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival.
- Published in:
- Liver International, 2023, v. 43, n. 7, p. 1497, doi. 10.1111/liv.15592
- By:
- Publication type:
- Article
Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
- Published in:
- Liver International, 2021, v. 41, n. 3, p. 535, doi. 10.1111/liv.14688
- By:
- Publication type:
- Article
Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis.
- Published in:
- International Journal of Experimental Pathology, 2014, v. 95, n. 3, p. 209, doi. 10.1111/iep.12076
- By:
- Publication type:
- Article
Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 11, p. 1366, doi. 10.1111/apt.17944
- By:
- Publication type:
- Article
Featured Cover.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 2, p. i, doi. 10.1111/apt.17864
- By:
- Publication type:
- Article
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 2, p. 186, doi. 10.1111/apt.17755
- By:
- Publication type:
- Article
Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 9, p. 1408, doi. 10.1111/apt.17226
- By:
- Publication type:
- Article
Cover Image.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 10, p. i, doi. 10.1111/apt.16402
- By:
- Publication type:
- Article
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 10, p. 1138, doi. 10.1111/apt.16336
- By:
- Publication type:
- Article
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 10, p. 1127, doi. 10.1111/apt.15533
- By:
- Publication type:
- Article
Systematic review with meta‐analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 6, p. 636, doi. 10.1111/apt.15148
- By:
- Publication type:
- Article
Altered Bile Acid Pool Using IBAT Inhibitors for Constipation: A Potentially Increased Risk of Malignancy.
- Published in:
- 2012
- By:
- Publication type:
- Letter
Challenges in the use of corticosteroids in the management of autoimmune hepatitis.
- Published in:
- Gastrointestinal Nursing, 2019, v. 17, p. S30, doi. 10.12968/gasn.2019.17.Sup10.S30
- By:
- Publication type:
- Article
Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis.
- Published in:
- Journal of Pathology, 2022, v. 258, n. 3, p. 227, doi. 10.1002/path.5994
- By:
- Publication type:
- Article
Appropriate patient selection in the management of common bile duct stones: when not to do ERCP.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Appropriate Patient Selection in the Management of Common Bile Duct Stones: When Not to Do ERCP.
- Published in:
- ISRN Surgery, 2012, p. 1, doi. 10.5402/2012/286365
- By:
- Publication type:
- Article
Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 12, p. 1508, doi. 10.1093/ecco-jcc/jjy130
- By:
- Publication type:
- Article
Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. S2, p. S641, doi. 10.1093/ecco-jcc/jjx145
- By:
- Publication type:
- Article
Risk Stratification in Primary Sclerosing Cholangitis: Does Size Matter?
- Published in:
- Digestive Diseases & Sciences, 2024, v. 69, n. 4, p. 1083, doi. 10.1007/s10620-023-08262-z
- By:
- Publication type:
- Article
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
- Published in:
- BMC Gastroenterology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12876-023-02653-2
- By:
- Publication type:
- Article
Challenges in the use of corticosteroids in the management of autoimmune hepatitis.
- Published in:
- British Journal of Hospital Medicine (17508460), 2019, v. 80, n. 10, p. 594, doi. 10.12968/hmed.2019.80.10.594
- By:
- Publication type:
- Article